Ki67 and p53 in gastrointestinal stromal tumors - GIST

Arquivos de Gastroenterologia

Lúcio Roberto De Oliveira Das Neves¹  Celina Tizuko Fujiyama Oshima¹  Ricardo Artigiani-neto¹  Gianni Yanaguibashi¹  Laércio Gomes Lourenço²  Nora Manoukian Forones¹ 

[1] ,Universidade Federal de São Paulo Surgery Department São Paulo SP ,Brazil

关键词: Gastrointestinal stromal tumors;    Ki-67 antigen;    Tumor suppressor protein p53;    Tumores do estroma gastrointestinal;    Antígeno Ki-67;    Proteína supressora de tumor p53;   

DOI  :  10.1590/S0004-28032009000200008

来源: SciELO

【 摘 要 】

CONTEXT: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Cellular proliferation and apoptosis is gaining importance for predicting prognosis in several cancers. OBJECTIVE: To investigate the Ki67 and p53 immunostaining in GISTs. METHODS: Specimens from 40 patients with GIST were assessed for immunohistochemical expression of Ki67 and p53. The tumors were divided according the risk of recurrence in two groups: I with high or intermediate risk and; II with low or very low risk. RESULTS: Among the 40 patients, 21 were men, the mean age was 56 years, 16 occurred in the small intestine and 13 in the stomach, 5 in the retroperitonium, 4 in the colon or rectum and 2 in the mesenterium. Thirty two tumors were from group I and 8 from group II. Half of the patients developed recurrence, being 90% of the group I (P = 0.114). The tumor Ki67 labelling index ranged from 0.02 to 0.35 (mean level 0.12). This index was marginally higher in the group I patients with recurrence (P = 0.09) compared to the patients of the same group without recurrence. p53 staining was expressed in 65% of the GISTs. A higher frequency of p53 and Ki67 had been found in the group I tumors when compared to the other group (P = 0.022; OR = 8.00 - IC 95%: 1.32-48.65). CONCLUSION: The most common site was the small intestine and 80% had a malignant potential justifying the high recurrence observed. No significant correlation was found between p53 and overall outcome of the patients. In group I patients, the evaluation Ki67LI may be a marker of prognosis. The positivity of both markers is higher among the patients with worst prognosis than in the others.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License